502 related articles for article (PubMed ID: 27493273)
1. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
2.
England CG; Jiang D; Ehlerding EB; Rekoske BT; Ellison PA; Hernandez R; Barnhart TE; McNeel DG; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):110-120. PubMed ID: 28821924
[TBL] [Abstract][Full Text] [Related]
3. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
4. Immuno-PET Imaging of
Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
[TBL] [Abstract][Full Text] [Related]
5.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
6. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
[TBL] [Abstract][Full Text] [Related]
7. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
8. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
10.
Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
[TBL] [Abstract][Full Text] [Related]
11. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
12. Preclinical PET imaging with the novel human antibody
Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
[TBL] [Abstract][Full Text] [Related]
13. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
14. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
[TBL] [Abstract][Full Text] [Related]
16. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
17. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
18. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
19. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
